CA3077189A1 - Modified cpf1 guide rna - Google Patents
Modified cpf1 guide rna Download PDFInfo
- Publication number
- CA3077189A1 CA3077189A1 CA3077189A CA3077189A CA3077189A1 CA 3077189 A1 CA3077189 A1 CA 3077189A1 CA 3077189 A CA3077189 A CA 3077189A CA 3077189 A CA3077189 A CA 3077189A CA 3077189 A1 CA3077189 A1 CA 3077189A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- sequence
- crrna
- cpfl
- extension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567123P | 2017-10-02 | 2017-10-02 | |
| US62/567,123 | 2017-10-02 | ||
| US201862617138P | 2018-01-12 | 2018-01-12 | |
| US62/617,138 | 2018-01-12 | ||
| US201862697327P | 2018-07-12 | 2018-07-12 | |
| US62/697,327 | 2018-07-12 | ||
| PCT/US2018/054027 WO2019070762A1 (en) | 2017-10-02 | 2018-10-02 | RNA GUIDE CPF1 MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3077189A1 true CA3077189A1 (en) | 2019-04-11 |
Family
ID=64184173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3077189A Pending CA3077189A1 (en) | 2017-10-02 | 2018-10-02 | Modified cpf1 guide rna |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200299689A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3692154A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020537540A (cg-RX-API-DMAC7.html) |
| CN (2) | CN111770994B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018345683B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020006601A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3077189A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL273595B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020003339A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202003083PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019070762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US11268092B2 (en) | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
| SG11202008956XA (en) * | 2018-03-14 | 2020-10-29 | Editas Medicine Inc | Systems and methods for the treatment of hemoglobinopathies |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| GB201913997D0 (en) * | 2019-09-27 | 2019-11-13 | Oxford Nanopore Tech Ltd | Method |
| US20230053028A1 (en) * | 2019-12-18 | 2023-02-16 | Editas Medicine, Inc. | Engineered cells for therapy |
| CN113234701B (zh) * | 2020-10-20 | 2022-08-16 | 珠海舒桐医疗科技有限公司 | 一种Cpf1蛋白及基因编辑系统 |
| EP4256040A4 (en) * | 2020-12-07 | 2025-11-12 | Inscripta Inc | NUCLEIC ACID-GUIDED GARN STABILIZATION IN NICKASE EDITION |
| EP4508211A2 (en) * | 2022-04-13 | 2025-02-19 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| US20240167029A1 (en) * | 2022-06-27 | 2024-05-23 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| WO2017070598A1 (en) * | 2015-10-23 | 2017-04-27 | Caribou Biosciences, Inc. | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| CA3062165A1 (en) * | 2017-05-04 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for gene editing in t cells using crispr/cpf1 |
-
2018
- 2018-10-02 WO PCT/US2018/054027 patent/WO2019070762A1/en not_active Ceased
- 2018-10-02 CA CA3077189A patent/CA3077189A1/en active Pending
- 2018-10-02 IL IL273595A patent/IL273595B1/en unknown
- 2018-10-02 MX MX2020003339A patent/MX2020003339A/es unknown
- 2018-10-02 EP EP18799900.8A patent/EP3692154A1/en active Pending
- 2018-10-02 US US16/753,293 patent/US20200299689A1/en active Pending
- 2018-10-02 CN CN201880077637.7A patent/CN111770994B/zh active Active
- 2018-10-02 AU AU2018345683A patent/AU2018345683B2/en active Active
- 2018-10-02 BR BR112020006601-0A patent/BR112020006601A2/pt unknown
- 2018-10-02 CN CN202510240123.0A patent/CN120290559A/zh active Pending
- 2018-10-02 SG SG11202003083PA patent/SG11202003083PA/en unknown
- 2018-10-02 JP JP2020539688A patent/JP2020537540A/ja active Pending
-
2024
- 2024-05-08 JP JP2024076160A patent/JP2024116119A/ja active Pending
-
2025
- 2025-04-11 AU AU2025202594A patent/AU2025202594A1/en active Pending
- 2025-09-10 IL IL323269A patent/IL323269A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL273595B1 (en) | 2025-10-01 |
| MX2020003339A (es) | 2020-11-06 |
| JP2024116119A (ja) | 2024-08-27 |
| SG11202003083PA (en) | 2020-05-28 |
| CN111770994A (zh) | 2020-10-13 |
| CN111770994B (zh) | 2025-03-18 |
| EP3692154A1 (en) | 2020-08-12 |
| AU2025202594A1 (en) | 2025-05-22 |
| AU2018345683B2 (en) | 2025-05-08 |
| US20200299689A1 (en) | 2020-09-24 |
| CN120290559A (zh) | 2025-07-11 |
| JP2020537540A (ja) | 2020-12-24 |
| KR20200106485A (ko) | 2020-09-14 |
| WO2019070762A1 (en) | 2019-04-11 |
| AU2018345683A1 (en) | 2020-04-23 |
| AU2025202594A9 (en) | 2025-09-04 |
| BR112020006601A2 (pt) | 2020-12-08 |
| IL273595A (en) | 2020-05-31 |
| IL323269A (en) | 2025-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111770994B (zh) | 修饰的cpf1引导rna | |
| US11667903B2 (en) | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/CAS9 | |
| US11268092B2 (en) | Structure-engineered guide RNA | |
| CN112585268B (zh) | 通过插入供体多核苷酸用于基因组编辑的组合物和方法 | |
| JP2023011676A (ja) | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 | |
| US20200347387A1 (en) | Compositions and methods for target nucleic acid modification | |
| CN114007655A (zh) | 用于细胞疗法的环状rna | |
| CA3026112A1 (en) | Cpf1 complexes with reduced indel activity | |
| EP3819377A1 (en) | Circular rna and uses thereof for inhibiting rna-binding proteins | |
| Yoon et al. | Re-engineering the mitochondrial genomes in mammalian cells | |
| KR102907044B1 (ko) | 변형된 cpf1 가이드 rna | |
| JP6795492B2 (ja) | ＣＬＣＮ７（ＡＤＯ２ ＣＬＣＮ７依存性）遺伝子変異によって引き起こされる常染色体優性大理石骨病２型（ＡＤＯ２）療法のための短鎖干渉ＲＮＡ（ｓｉＲＮＡ） | |
| EA047582B1 (ru) | Модифицированная направляющая рнк cpf1 | |
| Amirloo | Design and development of novel therapeutic interventions:'intelligent'catalytic systems for irreversible cleavage of disease-relevant RNA | |
| JP2025514327A (ja) | Ｃｒｉｓｐｒガイドｒｎａのための保護オリゴヌクレオチド | |
| Moore | Investigating the use of oligonucleotides for the treatment of muscular dystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230926 |